Atlas Trials

A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

Clinical trial NCT05269940 · COMPLETED

Trial details

NCT number
NCT05269940
Sponsor
Nanjing Zenshine Pharmaceuticals
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non Hodgkin LymphomaPeripheral T Cell LymphomaCLL/SLL
Start date
2022-02-17
Primary completion
2023-01-24
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.